Dual Plasmepsin-Targeting Antimalarial Agents Disrupt Multiple Stages of the Malaria Parasite Life Cycle (original) (raw)

Inhibitors of Plasmepsin II—potential antimalarial agents

Julien Grimont

Bioorganic & Medicinal Chemistry Letters, 2006

View PDFchevron_right

Plasmepsin 4-Deficient Plasmodium berghei Are Virulence Attenuated and Induce Protective Immunity against Experimental Malaria

Roberta Spaccapelo

The American Journal of Pathology, 2010

View PDFchevron_right

Inhibition of Plasmepsin V Activity Demonstrates Its Essential Role in Protein Export, PfEMP1 Display, and Survival of Malaria Parasites

Alan Cowman

Plos Biology, 2014

View PDFchevron_right

Plasmodium:Drug Discovery and Development—An Industrial Perspective

Dr. Robert Ridley

Experimental Parasitology, 1997

View PDFchevron_right

Identification of plasmepsin inhibitors as selective anti-malarial agents using ligand based drug design

Christopher Thomas Flood

Bioorganic & Medicinal Chemistry Letters, 2011

View PDFchevron_right

Clearance of Drug-Resistant Parasites as a Model for Protective Immunity in Plasmodium Falciparum Malaria

Yacouba Cissoko

The American Journal of Tropical Medicine and Hygiene, 2003

View PDFchevron_right

Picomolar Inhibition of Plasmepsin V, an Essential Malaria Protease, Achieved Exploiting the Prime Region

Ilaria Russo

PLOS ONE, 2015

View PDFchevron_right

Malaria Journal BioMed Central

Marc Coosemans

2009

View PDFchevron_right

Plasmepsins IX and X are essential and druggable mediators of malaria parasite egress and invasion

Ilaria Russo

Science (New York, N.Y.), 2017

View PDFchevron_right

Malaria: Patterns of relapse and resistance

Dr Muheet .Alam

Journal of King Saud University - Science, 2010

View PDFchevron_right

Suppression of Plasmodium MIF‐CD74 signaling protects against severe malaria

Alvaro Garcia junior

The FASEB Journal, 2021

View PDFchevron_right

A multistage antimalarial targets the plasmepsins IX and X essential for invasion and egress

Paco Pino

Science

View PDFchevron_right

Apical Surface Expression of Aspartic Protease Plasmepsin 4, a Potential Transmission-blocking Target of the Plasmodium Ookinete

John Dame

Journal of Biological Chemistry, 2010

View PDFchevron_right

Plasmepsin 4, the food vacuole aspartic proteinase found in all Plasmodium spp. infecting man

John Dame

Molecular and Biochemical Parasitology, 2003

View PDFchevron_right

Impaired fitness of drug-resistant malaria parasites: evidence and implication on drug-deployment policies

Hamza Babiker

Expert Review of Anti-infective Therapy, 2009

View PDFchevron_right

Anti-Malarial Drug Development and Diffusion in an Era of Multidrug Resistance

Ellen Moors

Oxford University Press eBooks, 2020

View PDFchevron_right

Malaria and COVID-19: commonalities, intersections and implications for sustaining malaria control

Catherine Falade

Pan African Medical Journal, 2020

View PDFchevron_right

Malaria: What are the Needs for Diagnosis, Treatment and Control?

basha ayele

Biology and Medicine, 2016

View PDFchevron_right

Recent advances in identification of potential drug targets and development of novel drugs in protozoal diseases. Part IV. Apicomplexans and Plasmodium spp

Sherif Abaza

Parasitologists United Journal, 2022

View PDFchevron_right

A candidate antibody drug for prevention of malaria

Daniel Emerling

Nature Medicine, 2024

View PDFchevron_right

Preliminary in silico study of a novel paratransgenic weapon against malaria

Michelle Fidelia

Deleted Journal, 2024

View PDFchevron_right

Inter-relação do ritmo e da ação de drogas antimaláricas na infecção da malária de roedores

Piero Bagnaresi

View PDFchevron_right

Structure of the aspartic protease plasmepsin 4 from the malarial parasite Plasmodium malariae bound to an allophenylnorstatine-based inhibitor

Ben Dunn

Acta Crystallographica Section D Biological Crystallography, 2006

View PDFchevron_right

Prevention or treatment? The case of malaria

Jean-Claude Berthélemy

Economics Letters, 2015

View PDFchevron_right

Development of vaccines against malaria

Klavs Berzins

International Journal of Immunopharmacology, 1994

View PDFchevron_right

Malarial Subjects

Rohan Deb Roy

2017

View PDFchevron_right

Malaria vaccines: if at first you don't succeed…

David Roos

Trends in Parasitology, 2004

View PDFchevron_right

Treatment of Chronic Asymptomatic Plasmodium falciparum Infection Does Not Increase the Risk of Clinical Malaria Upon Reinfection

Didier Doumtabe

Clinical Infectious Diseases, 2016

View PDFchevron_right

Emergence of Undetectable Malaria Parasites: A Threat under the Radar amid the COVID-19 Pandemic?

abdulrahman mohammed

The American Journal of Tropical Medicine and Hygiene, 2020

View PDFchevron_right

Asymptomatic Natural Human Infections With the Simian Malaria Parasites Plasmodium cynomolgi and Plasmodium knowlesi

chanon kunasol

The Journal of Infectious Diseases, 2018

View PDFchevron_right

Role of Antibody Diversity in the Management of Malaria Parasite Invasion

Farouk Muhammad

2019

View PDFchevron_right

A protein interaction network of the malaria parasite Plasmodium falciparum

Sudhir Sahasrabudhe

Nature, 2005

View PDFchevron_right

Generation of an affinity matrix useful in the purification of natural inhibitors of plasmepsin II, an antimalarial-drug target

Angel Rafael Ramirez Ramirez

Biotechnology and Applied Biochemistry, 2009

View PDFchevron_right

Functional, structural, and immunological compartmentalisation of malaria invasive proteins

LUIS VARGAS

Biochemical and Biophysical Research Communications, 2007

View PDFchevron_right

Irreversible effect of cysteine protease inhibitors on the release of malaria parasites from infected erythrocytes

Julia Mazar

Cellular Microbiology, 2009

View PDFchevron_right